Eight Billion Immunology Deal
Sanofi and Regeneron Expand Their Immunology Partnership Through an Eight Billion Dollar Deal
Anonymous
Key Points
1
Dupixent is currently used by more than 1.5 million people across nine indications and generated almost $18 billion in sales last year.
2
Under the new collaboration, Regeneron will lead research and development, while Sanofi will lead global commercialization.
3
The three preclinical antibody programs are expected to enter clinical studies in 2027.
4
Regeneron has an option to add Sanofi’s investigational lunsekimig to the collaboration after its Phase 3 COPD studies are completed.
Sanofi and Regeneron are expanding their immunology partnership with an $8 billion deal to develop four long-acting antibodies targeting type 2 inflammation BioCentury. The lead candidate, REGN20423, is already in Phase 1 testing for atopic dermatitis. Regeneron will receive $1 billion upfront and could earn up to $7 billion more through development and sales milestones Seeking Alpha.
The deal extends the companies' successful Dupixent partnership, which has generated nearly $18 billion in annual sales across nine indications Stock Titan. The new antibodies are designed to keep the alliance strong after Dupixent's patent expires in the 2030s.
Dupixent's Massive Success Sets High Bar
Dupixent is one of the industry's blockbuster drugs. More than 1.5 million patients worldwide now use it Aktien Sensor. Last year alone, the drug pulled in almost $18 billion in sales across nine different indications, from atopic dermatitis to asthma Stock Titan.
That success makes it the foundation of Sanofi and Regeneron's relationship. But every drug faces an expiration date. The partners now need new products ready to launch as Dupixent's patent protection ends in the 2030s BioCentury.
Four Antibodies Target Type 2 Inflammation Pathways
The new deal adds four long-acting antibodies to the alliance WebWire. REGN20423, already in Phase 1 trials, targets IL-13 for atopic dermatitis. The three other programs target IL-4, IL-4 receptor alpha, and a combination of IL-4 and IL-13 Stock Titan. All three preclinical programs are expected to enter human studies in 2027.
Regeneron Gets $1 Billion Upfront, Splits Profits Evenly
Regeneron receives a $1 billion upfront payment and can earn up to $7 billion in milestone payments as the drugs advance Stock Titan. The companies will split development costs equally and divide profits from any approved products 50-50 WebWire. Regeneron will handle research and development, while Sanofi leads global commercialization.
The original Dupixent deal remains unchanged. Regeneron also has an option to add Sanofi's lunsekimig, an experimental COPD drug, to the collaboration once Phase 3 studies wrap up Seeking Alpha.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
24
Articles
90
Reach
114
A
AnonymousAuthor
